S-W. Kim - Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 46 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Abstract 3727: Synergistic effect of CD47 blockade and EPHA3 treatment on recurrent head and neck cancers

Song Hee Kim, Myung Woul Han,Ji Won Kim,Seong Who Kim

Cancer Researchno. 6_Supplement (2024): 3727-3727

引用0浏览0引用

12MO Patterns of response in metastatic (m) NSCLC after 2 and 4 cycles of chemotherapy (CT), alone or with durvalumab (D) ± tremelimumab (T), in the phase III POSEIDON study

N. Reinmuth,B.C. Cho, A. Luft, J.A. Alatorre Alexander,S. Lucien Geater, K. Laktionov,S-W. Kim, G. Ursol, M. Hussein, F.L. Lim,C-T. Yang, L.H. Araujo,

JOURNAL OF THORACIC ONCOLOGYno. 4 (2023): S44-S46

引用0浏览0引用

1333P A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations

M.H. Hong, A.I. Spira, K.H. Lee, E.K. Cho,J-Y. Han, B.Y. Shim,J-S. Lee, S.C-H. Kao,S-W. Kim, A. Khattak, M. Patel, R. Xu,

Annals of Oncology (2023): S769-S769

引用0浏览0引用

Amivantamab plus chemotherapy vs chemotherapy as a first-line treatment among Asian patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): PAPILLON subgroup analysis

C. Zhou, K. Tang, B. Liu,S-W. Kim, S. Kitazono, A. Ono, M. Thiagarajan,J-Y. Hung, M. Boyer, J. Xie, A. Bhattacharya, M. Baig,

Annals of Oncology (2023): S1668-S1669

引用0浏览0引用

1391P Capmatinib vs docetaxel as second- or third-line (2/3L) therapy in patients (pts) with METex14-mutated advanced NSCLC (aNSCLC): The GeoMETry-III trial

O.J. Juan Vidal, M.K. Singhal,R.M. Alvarez, F.L. Cecere, P-J. Souquet,S-W. Kim, A. Robeva, A. Jary, S. Glaser, M. Miskic, J. Wolf

Annals of Oncology (2023): S797-S797

引用0浏览0引用

Trastuzumab deruxtecan (T-DXd) in Asian patients (Pts) with human epidermal growth factor receptor 2 (HER2; ERBB2)mutant (HER2m) metastatic non-small cell lung cancer (mNSCLC): Subgroup analysis of DESTINYeLung02 (DL-02)

Y. Goto, K. Goto, T. Kubo, K. Ninomiya,S-W. Kim,M-J. Ahn, K. Nakagawa, H. Hayashi, J. Shimizu,D-W. Kim,J. C-H. Yang, C-H. S. Kuo,

ANNALS OF ONCOLOGY (2023): S1666-S1667

引用0浏览0引用

Treatment (tx) patterns and outcomes in resectable early-stage EGFR-mutated (EGFRm) NSCLC in South Korea: Subgroup analysis of a global real-world (rw) study

M-J. Ahn,J. H. Kang,S-W. Kim, D. Kahangire, S. P. Nagar, K. L. Davis, M. Jimenez, M. Seo,M. Jung, M. Sandelin,B. C. Cho

ANNALS OF ONCOLOGY (2023): S1650-S1651

引用0浏览0引用

A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC

S. M. Lim,B. C. Cho,J-Y. Han,S-W. Kim, K. H. Lee, M. Nagasaka, T. R. Baisamut, A. Jo, E. Seah, C. Kim,S-H. I. Ou

Annals of Oncology (2023): S1704-S1705

引用0浏览0引用

Alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naive advanced ALK plus non-small cell lung cancer (NSCLC): 5-year update from the phase III ALESIA study

C. Zhou, Y. Lu,S-W. Kim, T. Baisamut (Reungwetwattana), J. Zhou, Y. Zhang, J. He,J. Yang,Y. Cheng,S-H. Lee,J. Chang, J. Fang,

ANNALS OF ONCOLOGY（2022）

引用0浏览0引用

13P Durvalumab + chemotherapy in patients (pts) with advanced EGFR mutation-positive (EGFRm) NSCLC whose disease progressed on first-line (1L) osimertinib: An ORCHARD study interim analysis

B. C. Cho, M. J. Ahn, C. Baik, R. Garcia,J. W. Goldman,S-W. Kim, J. S. Lee, M. Nishio, S. Ponce, R. Salgia,S. Teraoka, T. Yoshida,

Annals of Oncology（2022）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn